BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

被引:2291
作者
Reig, Maria [1 ,2 ]
Forner, Alejandro [1 ,2 ]
Rimola, Jordi [3 ]
Ferrer-Fabrega, Joana [4 ]
Burrel, Marta [5 ]
Garcia-Criado, Angeles [3 ]
Kelley, Robin K. [6 ]
Galle, Peter R. [7 ]
Mazzaferro, Vincenzo [8 ,9 ]
Salem, Riad [10 ]
Sangro, Bruno [2 ,11 ]
Singal, Amit G. [12 ]
Vogel, Arndt [13 ]
Fuster, Josep [2 ,4 ]
Ayuso, Carmen [2 ,3 ]
Bruix, Jordi [1 ,2 ]
机构
[1] Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, BCLC Grp,Liver Unit,ICMDM, Barcelona, Spain
[2] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain
[3] Univ Barcelona, Hosp Clin Barcelona, CDI, BCLC Grp,Radiol Dept, Barcelona, Spain
[4] Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, BCLC Grp,Surg Dept,ICMDM, Barcelona, Spain
[5] Univ Barcelona, BCLC Grp, Vasc Dept, CDI,Hosp Clin Barcelona,Barcelona Univ, Barcelona, Spain
[6] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[7] Mainz Univ, Dept Internal Med, Med Ctr, Mainz, Germany
[8] Univ Milan, Dept Oncol, Milan, Italy
[9] Fdn IRCCS Ist Nazl Tumori, HPB Surg & Liver Transplantat, Milan, Italy
[10] Northwestern Univ, Dept Radiol, Sect Intervent Radiol, Chicago, IL USA
[11] Clin Univ Navarra, Liver Unit, Pamplona, Spain
[12] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA
[13] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
关键词
HCC; survival; BCLC; ablation; surgery; liver transplantation TACE; TARE; systemic treatment; ALBI score; AFP; RANDOMIZED CONTROLLED-TRIAL; UNRESECTABLE HEPATOCELLULAR-CARCINOMA; CLINICAL DECISION-MAKING; OPEN LIVER RESECTION; RADIOFREQUENCY ABLATION; TRANSARTERIAL CHEMOEMBOLIZATION; ALPHA-FETOPROTEIN; SURGICAL RESECTION; HEPATIC RESECTION; PORTAL-HYPERTENSION;
D O I
10.1016/j.jhep.2021.11.018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management. (C) 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:681 / 693
页数:13
相关论文
共 127 条
  • [31] Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials
    Facciorusso, Antonio
    Bellanti, Francesco
    Villani, Rosanna
    Salvatore, Veronica
    Muscatiello, Nicola
    Piscaglia, Fabio
    Vendemiale, Gianluigi
    Serviddio, Gaetano
    [J]. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2017, 5 (04) : 511 - 518
  • [32] A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma
    Feng, Kai
    Yan, Jun
    Li, Xiaowu
    Xia, Feng
    Ma, Kuansheng
    Wang, Shuguang
    Bie, Ping
    Dong, Jiahong
    [J]. JOURNAL OF HEPATOLOGY, 2012, 57 (04) : 794 - 802
  • [33] Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival
    Ferrer-Fabrega, Joana
    Sampson-Davila, Jaime
    Forner, Alejandro
    Sapena, Victor
    Diaz, Alba
    Vilana, Ramon
    Navasa, Miquel
    Fondevila, Constantino
    Miquel, Rosa
    Ayuso, Carmen
    Garcia-Valdecasas, Juan Carlos
    Bruix, Jordi
    Reig, Maria
    Fuster, Josep
    [J]. JOURNAL OF HEPATOLOGY, 2021, 75 (05) : 1154 - 1163
  • [34] Prospective Validation of Ab Initio Liver Transplantation in Hepatocellular Carcinoma Upon Detection of Risk Factors for Recurrence After Resection
    Ferrer-Fabrega, Joana
    Forner, Alejandro
    Liccioni, Alexandre
    Miquel, Rosa
    Molina, Victor
    Navasa, Miquel
    Fondevila, Constantino
    Carlos Garcia-Valdecasas, Juan
    Bruix, Jordi
    Fuster, Josep
    [J]. HEPATOLOGY, 2016, 63 (03) : 839 - 849
  • [35] Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis
    Ferrusquia-Acosta, Jose
    Bassegoda, Octavi
    Turco, Laura
    Reverter, Enric
    Pellone, Monica
    Bianchini, Marcello
    Perez-Campuzano, Valeria
    Ripoll, Enric
    Garcia-Criado, Angeles
    Graupera, Isabel
    Garcia-Pagan, Juan Carlos
    Schepis, Filippo
    Senzolo, Marco
    Hernandez-Gea, Virginia
    [J]. JOURNAL OF HEPATOLOGY, 2021, 74 (04) : 811 - 818
  • [36] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed O.
    Li, Daneng
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Liu, Juan
    Huang, Chen
    Mulla, Sohail
    Wang, Yulei
    Lim, Ho Yeong
    Zhu, Andrew X.
    Cheng, Ann-Lii
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) : 1894 - 1905
  • [37] Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
    Finn, Richard S.
    Ryoo, Baek-Yeol
    Merle, Philippe
    Kudo, Masatoshi
    Bouattour, Mohamed
    Lim, Ho Yeong
    Breder, Valeriy
    Edeline, Julien
    Chao, Yee
    Ogasawara, Sadahisa
    Yau, Thomas
    Garrido, Marcelo
    Chan, Stephen L.
    Knox, Jennifer
    Daniele, Bruno
    Ebbinghaus, Scot W.
    Chen, Erluo
    Siegel, Abby B.
    Zhu, Andrew X.
    Cheng, Ann-Lii
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (03) : 193 - +
  • [38] Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
    Finn, Richard S.
    Merle, Philippe
    Granito, Alessandro
    Huang, Yi-Hsiang
    Bodoky, Gyorgy
    Pracht, Marc
    Yokosuka, Osamu
    Rosmorduc, Olivier
    Gerolami, Rene
    Caparello, Chiara
    Cabrera, Roniel
    Chang, Charissa
    Sun, Weijing
    LeBerre, Marie-Aude
    Baumhauer, Annette
    Meinhardt, Gerold
    Bruix, Jordi
    [J]. JOURNAL OF HEPATOLOGY, 2018, 69 (02) : 353 - 358
  • [39] Treatment of intermediate-stage hepatocellular carcinoma
    Fomer, Alejandro
    Gilabert, Marine
    Bruix, Jordi
    Raoul, Jean-Luc
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (09) : 525 - 535
  • [40] Hepatocellular carcinoma
    Forner, Alejandro
    Reig, Maria
    Bruix, Jordi
    [J]. LANCET, 2018, 391 (10127) : 1301 - 1314